1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Transdermal Patches Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increased use of transdermal patches to treat chronic conditions worldwide
5.1.1.2. Rising preference for controlled drug release and non-invasive drug delivery solutions
5.1.1.3. Growing number of government approvals for transdermal patches
5.1.2. Restraints
5.1.2.1. High costs associated with transdermal patches
5.1.3. Opportunities
5.1.3.1. Ongoing research and development for advanced and highly efficient transdermal drug delivery patches
5.1.3.2. Emerging advances in the formulation and manufacturing of transdermal patches
5.1.4. Challenges
5.1.4.1. Limitations associated with transdermal drugs along with product recalls
5.2. Market Segmentation Analysis
5.2.1. Product: Significant penetration of Multi-layer Drug-in-Adhesive patches
5.2.2. Type: Extensive requirement for nicotine transdermal patches
5.2.3. Technology: Utilization of chemical enhancers to improve transdermal patch efficacy
5.2.4. Application: Expanding use of transdermal patches for hormonal therapy
5.2.5. Distribution Channel: Proliferation of transdermal patches on eCommerce platforms
5.2.6. End Users: Increasing prescription of transdermal patches in hospitals
5.3. Market Trend Analysis
5.3.1. Supportive government approval landscape for transdermal patches in the Americas
5.3.2. Growing prevalence of chronic pain and diabetes propelling the growth of transdermal patches in the APAC region
5.3.3. Improving healthcare infrastructure to increase access of innovative transdermal patches in the EMEA region
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Transdermal Patches Market, by Product
6.1. Introduction
6.2. Matrix
6.3. Multi-layer Drug-in-Adhesive
6.4. Reservoir
6.5. Single-layer Drug-in-Adhesive
7. Transdermal Patches Market, by Type
7.1. Introduction
7.2. Buprenorphine Transdermal Patch
7.3. Clonidine Transdermal Patch
7.4. Fentanyl Transdermal Patch
7.5. Nicotine Transdermal Patch
7.6. Oxybutynin Transdermal Patch
8. Transdermal Patches Market, by Technology
8.1. Introduction
8.2. Chemical Enhancers
8.3. Electric Current
8.4. Mechanical Arrays
8.5. Thermal Ablation
9. Transdermal Patches Market, by Application
9.1. Introduction
9.2. Hormonal Therapy
9.3. Overactive Bladder
9.4. Pain Relief
9.5. Smoking Reduction & Cessation Aid
10. Transdermal Patches Market, by Distribution Channel
10.1. Introduction
10.2. Offline
10.3. Online
11. Transdermal Patches Market, by End Users
11.1. Introduction
11.2. Clinics
11.3. Home Care Settings
11.4. Hospitals
12. Americas Transdermal Patches Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Transdermal Patches Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam
14. Europe, Middle East & Africa Transdermal Patches Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom
15. Competitive Landscape
15.1. FPNV Positioning Matrix
15.2. Market Share Analysis, By Key Player
15.3. Competitive Scenario Analysis, By Key Player
15.3.1. Merger & Acquisition
15.3.1.1. Almirall Acquires Rights To Distribute Alzheimer’s Treatment In Spain For An Initial EUR 45 Million
15.3.1.2. LTS Completes its Entry into Large Molecule Drug Delivery with the Acquisition of the Sorrel Wearable Injection Device Business
15.3.1.3. The Addition of Tesa Labtec GmbH Marks a Cornerstone in AdhexPharma’s Growth Path
15.3.2. Agreement, Collaboration, & Partnership
15.3.2.1. Corium and Lotus Pharmaceutical Enter into Exclusive License Agreement for Innovative Alzheimer’s Disease Treatment ADLARITY in Multiple Markets Across Asia
15.3.2.2. Bionxt Signs Clinical Study Agreement and Commences Manufacture of Clinical Samples for Study of Transdermal Rotigotine Patch for Parkinson’s Disease
15.3.3. New Product Launch & Enhancement
15.3.3.1. DifGen Pharmaceuticals Launches A Second Product – Buprenorphine Transdermal System From Its U.S. Manufacturing Site Aveva Drug Delivery Systems; Expanding Its Portfolio Of Manufacturing & Marketing U.S. Made Transdermal Patches And Sublingual Films
15.3.3.2. Luye Pharma Ltd Launches New Alzheimer’s Treatment In The UK
15.3.4. Investment & Funding
15.3.4.1. Corsair Pharma Announces USD 23 Million Series B Financing to Advance Clinical Trials in Pulmonary Arterial Hypertension
15.3.4.2. Vaxess Raises USD 9 Million to Accelerate mRNA Vaccine Patch Development
15.3.4.3. LTS Lohmann Leads Investment in Needle-Free Delivery Specialist
15.3.5. Award, Recognition, & Expansion
15.3.5.1. Dexmedetomidine Transdermal Patch Fast Tracked for Postop Pain Management
15.3.5.2. BioNxt Receives Approval for European Clinical Study of Transdermal Rotigotine Patch for Parkinson’s Disease
16. Competitive Portfolio
16.1. Key Company Profiles
16.1.1. AbbVie Inc.
16.1.2. AdhexPharma SAS
16.1.3. ALVOGEN
16.1.4. Amneal Pharmaceuticals, Inc.
16.1.5. Bayer AG
16.1.6. BioNxt Solutions Inc.
16.1.7. Bliss GVS Pharma Ltd.
16.1.8. Boehringer Ingelheim International GmbH
16.1.9. Corium, Inc.
16.1.10. Corsair Pharma, Inc.
16.1.11. DifGen Pharmaceuticals LLC
16.1.12. Endo International plc
16.1.13. Gedeon Richter Plc
16.1.14. GlaxoSmithKline Plc
16.1.15. Icure Pharmaceutical Inc.
16.1.16. Johnson & Johnson Services, Inc.
16.1.17. LAVIPHARM GROUP HOLDING S.A.
16.1.18. Luye Pharma Group Ltd
16.1.19. Medherant Limited
16.1.20. Nitto Denko Corporation
16.1.21. Novartis AG
16.1.22. Noven Pharmaceuticals, Inc. by Hisamitsu Pharmaceutical Co., Inc.
16.1.23. Nutriband Inc
16.1.24. Perrigo Company plc
16.1.25. ProSolus, Inc.
16.1.26. Purdue Pharma L.P.
16.1.27. Sparsha Pharma International Pvt Ltd
16.1.28. Tapemark by LTS Lohmann Therapie-Systeme AG
16.1.29. Teikoku Seiyaku Co., Ltd.
16.1.30. Tesa SE by Beiersdorf AG
16.1.31. Teva Pharmaceutical Industries Ltd.
16.1.32. UCB S.A.
16.1.33. Viatris Inc.
16.1.34. Zydus Group
16.2. Key Product Portfolio
17. Appendix
17.1. Discussion Guide
17.2. License & Pricing
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
